Overview

This trial is active, not recruiting.

Condition type-2 diabetes
Phase phase 3
Sponsor University of Palermo
Start date June 2012
End date December 2015
Trial size 300 participants
Trial identifier NCT01715428, LIRAGLUTIDE UNIPA

Summary

Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective
Arm
administration of liraglutide at 1.2 mg/daily

Primary Outcomes

Measure
carotid intima-media thickness
time frame: every four months for a total period of 2 years

Secondary Outcomes

Measure
changes in oxidative stress, ghrelin, atherogenic lipoproteins, heat shock proteins
time frame: after 2 months of therapy

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - patients with a diagnosis of type-2 diabetes Exclusion Criteria: - severe hepatic or renal diseases

Additional Information

Official title Effects of Liraglutide on Cardio-Metabolic Risk Markers
Description In details, we will evaluate the effects of liraglutide on carotid-intima media thickness, oxidative stress, ghrelin, heat shock proteins and lipoproteins.
Trial information was received from ClinicalTrials.gov and was last updated in June 2015.
Information provided to ClinicalTrials.gov by University of Palermo.